Nacho Aguilo

Zaragoza, AR, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications

Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials.

Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: January 14, 2026

Corrigendum to "Correlation between systemic allergen desensitisation and long-term asthma protection in mice following intravenous administration of the live tuberculosis vaccine MTBVAC" [EBioMedicine 107(2024)105272] DOI: https://doi.org/10.1016/j.ebiom.2024.105272.

Corrigendum to "Correlation between systemic allergen desensitisation and long-term asthma protection in mice following intravenous administration of the live tuberculosis vaccine MTBVAC" [EBioMedicine 107(2024)105272] DOI: https://doi.org/10.1016/j.ebiom.2024.105272.

Journal: EBioMedicine
Published: February 27, 2025

NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice.

NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice.

Journal: Cancer gene therapy
Published: November 15, 2024

Selective expansion of anti-tumor innate lymphocytes in long-term cultures after a single BCG pulse.

Selective expansion of anti-tumor innate lymphocytes in long-term cultures after a single BCG pulse.

Journal: Methods in cell biology
Published: November 08, 2024

Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine.

Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine.

Journal: NPJ vaccines
Published: September 20, 2024

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.

Journal: NPJ vaccines
Published: July 04, 2024

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting.

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting.

Journal: EBioMedicine
Published: May 28, 2024

BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors.

BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors.

Journal: Scientific reports
Published: March 19, 2024

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.

Journal: Frontiers in immunology
Published: February 17, 2024

Correlation between systemic allergen desensitisation and long-term asthma protection in mice following intravenous administration of the live tuberculosis vaccine MTBVAC.

Correlation between systemic allergen desensitisation and long-term asthma protection in mice following intravenous administration of the live tuberculosis vaccine MTBVAC.

Journal: EBioMedicine
Published: December 12, 2023

Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial.

Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial.

Journal: The Lancet. Global health
Published: September 18, 2023

Heat-killed Mycobacterium tuberculosis induces trained immunity in vitro and in vivo administered systemically or intranasally.

Heat-killed Mycobacterium tuberculosis induces trained immunity in vitro and in vivo administered systemically or intranasally.

Journal: iScience
Published: June 19, 2023
Showing 1-12 of 60

Last Updated: 09/26/2026